CN118873569B - Composite pharmaceutical composition and its application and method for controlling sword flea outbreak - Google Patents
Composite pharmaceutical composition and its application and method for controlling sword flea outbreak Download PDFInfo
- Publication number
- CN118873569B CN118873569B CN202410897859.0A CN202410897859A CN118873569B CN 118873569 B CN118873569 B CN 118873569B CN 202410897859 A CN202410897859 A CN 202410897859A CN 118873569 B CN118873569 B CN 118873569B
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- babylonia
- parts
- composite
- composite pharmaceutical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 62
- 239000002131 composite material Substances 0.000 title claims abstract description 40
- 238000000034 method Methods 0.000 title claims abstract description 27
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims abstract description 36
- 230000004083 survival effect Effects 0.000 claims abstract description 26
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 claims abstract description 19
- 229940093265 berberine Drugs 0.000 claims abstract description 19
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 claims abstract description 19
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims abstract description 18
- 229960004889 salicylic acid Drugs 0.000 claims abstract description 18
- 235000003145 Hippophae rhamnoides Nutrition 0.000 claims abstract description 15
- 238000002360 preparation method Methods 0.000 claims abstract description 7
- 229930003935 flavonoid Natural products 0.000 claims abstract 4
- 150000002215 flavonoids Chemical class 0.000 claims abstract 4
- 235000017173 flavonoids Nutrition 0.000 claims abstract 4
- 241000606434 Babylonia Species 0.000 claims description 77
- 241000229143 Hippophae Species 0.000 claims description 16
- 239000003814 drug Substances 0.000 claims description 11
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 10
- 239000000654 additive Substances 0.000 claims description 10
- 229960005069 calcium Drugs 0.000 claims description 10
- 239000011575 calcium Substances 0.000 claims description 10
- 229910052791 calcium Inorganic materials 0.000 claims description 10
- 230000000996 additive effect Effects 0.000 claims description 8
- 235000015497 potassium bicarbonate Nutrition 0.000 claims description 6
- 239000011736 potassium bicarbonate Substances 0.000 claims description 6
- 229910000028 potassium bicarbonate Inorganic materials 0.000 claims description 6
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 claims description 6
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 5
- 239000011591 potassium Substances 0.000 claims description 5
- 229910052700 potassium Inorganic materials 0.000 claims description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 4
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 2
- 235000010216 calcium carbonate Nutrition 0.000 claims description 2
- 239000001110 calcium chloride Substances 0.000 claims description 2
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 2
- 235000011148 calcium chloride Nutrition 0.000 claims description 2
- 239000004227 calcium gluconate Substances 0.000 claims description 2
- 235000013927 calcium gluconate Nutrition 0.000 claims description 2
- 229960004494 calcium gluconate Drugs 0.000 claims description 2
- 239000001506 calcium phosphate Substances 0.000 claims description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 claims description 2
- 235000011010 calcium phosphates Nutrition 0.000 claims description 2
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 claims description 2
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 235000019796 monopotassium phosphate Nutrition 0.000 claims description 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 claims description 2
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 claims description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 2
- 235000011181 potassium carbonates Nutrition 0.000 claims description 2
- 239000001103 potassium chloride Substances 0.000 claims description 2
- 235000011164 potassium chloride Nutrition 0.000 claims description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 2
- YZCKVEUIGOORGS-IGMARMGPSA-N Protium Chemical compound [1H] YZCKVEUIGOORGS-IGMARMGPSA-N 0.000 claims 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims 1
- 235000019700 dicalcium phosphate Nutrition 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 43
- 241000237858 Gastropoda Species 0.000 abstract description 11
- 238000009395 breeding Methods 0.000 abstract description 10
- 230000001488 breeding effect Effects 0.000 abstract description 10
- 230000008569 process Effects 0.000 abstract description 8
- 241000195493 Cryptophyta Species 0.000 abstract description 4
- 241001247203 Syngnathidae Species 0.000 abstract description 2
- 241000238571 Cladocera Species 0.000 abstract 3
- 241000737252 Botrychium Species 0.000 abstract 1
- 240000000950 Hippophae rhamnoides Species 0.000 abstract 1
- 241000238578 Daphnia Species 0.000 description 29
- 230000000052 comparative effect Effects 0.000 description 22
- 210000001320 hippocampus Anatomy 0.000 description 17
- 241000123650 Botrytis cinerea Species 0.000 description 15
- 150000001875 compounds Chemical class 0.000 description 14
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 13
- 229930003944 flavone Natural products 0.000 description 13
- 150000002212 flavone derivatives Chemical class 0.000 description 13
- 235000011949 flavones Nutrition 0.000 description 13
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 13
- 230000012010 growth Effects 0.000 description 11
- 101000831205 Danio rerio Dynein axonemal assembly factor 11 Proteins 0.000 description 10
- 102100024282 Dynein axonemal assembly factor 11 Human genes 0.000 description 10
- 241001559542 Hippocampus hippocampus Species 0.000 description 10
- 101000831210 Homo sapiens Dynein axonemal assembly factor 11 Proteins 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- 230000000694 effects Effects 0.000 description 8
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 6
- 229910052760 oxygen Inorganic materials 0.000 description 6
- 239000001301 oxygen Substances 0.000 description 6
- 241000251468 Actinopterygii Species 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 239000004576 sand Substances 0.000 description 5
- 238000012258 culturing Methods 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 238000011031 large-scale manufacturing process Methods 0.000 description 4
- 239000013535 sea water Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 241000920062 Babylonia areolata Species 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 241001494246 Daphnia magna Species 0.000 description 3
- 208000035240 Disease Resistance Diseases 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000009344 polyculture Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000002352 surface water Substances 0.000 description 3
- 235000003935 Hippophae Nutrition 0.000 description 2
- 241001248590 Isaria Species 0.000 description 2
- 241000237852 Mollusca Species 0.000 description 2
- 241000554482 Pteris longifolia Species 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 238000009360 aquaculture Methods 0.000 description 2
- 244000144974 aquaculture Species 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000004568 cement Substances 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 description 2
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229960001952 metrifonate Drugs 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 238000002791 soaking Methods 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- NFACJZMKEDPNKN-UHFFFAOYSA-N trichlorfon Chemical compound COP(=O)(OC)C(O)C(Cl)(Cl)Cl NFACJZMKEDPNKN-UHFFFAOYSA-N 0.000 description 2
- 241000238421 Arthropoda Species 0.000 description 1
- 241000920060 Babylonia formosae Species 0.000 description 1
- 241001522722 Buccinidae Species 0.000 description 1
- 241000397426 Centroberyx lineatus Species 0.000 description 1
- 241001672694 Citrus reticulata Species 0.000 description 1
- 241000239250 Copepoda Species 0.000 description 1
- 241000238424 Crustacea Species 0.000 description 1
- UBSCDKPKWHYZNX-UHFFFAOYSA-N Demethoxycapillarisin Natural products C1=CC(O)=CC=C1OC1=CC(=O)C2=C(O)C=C(O)C=C2O1 UBSCDKPKWHYZNX-UHFFFAOYSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241001559553 Hippocampus abdominalis Species 0.000 description 1
- 241001559546 Hippocampus erectus Species 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- GQODBWLKUWYOFX-UHFFFAOYSA-N Isorhamnetin Natural products C1=C(O)C(C)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 GQODBWLKUWYOFX-UHFFFAOYSA-N 0.000 description 1
- 241000243714 Lutosa Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000186243 Metridia Species 0.000 description 1
- 241000238003 Neogastropoda Species 0.000 description 1
- BNSDRLNDXQPSGV-UHFFFAOYSA-N O.O.Cl.C=1C=CCN2C=CC=CC12 Chemical compound O.O.Cl.C=1C=CCN2C=CC=CC12 BNSDRLNDXQPSGV-UHFFFAOYSA-N 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 235000005128 Sapium sebiferum Nutrition 0.000 description 1
- 244000057114 Sapium sebiferum Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003640 drug residue Substances 0.000 description 1
- 238000012851 eutrophication Methods 0.000 description 1
- 238000004880 explosion Methods 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000000971 hippocampal effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- IZQSVPBOUDKVDZ-UHFFFAOYSA-N isorhamnetin Chemical compound C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 IZQSVPBOUDKVDZ-UHFFFAOYSA-N 0.000 description 1
- 235000008800 isorhamnetin Nutrition 0.000 description 1
- 235000008777 kaempferol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 1
- 208000009091 myxoma Diseases 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01G—HORTICULTURE; CULTIVATION OF VEGETABLES, FLOWERS, RICE, FRUIT, VINES, HOPS OR SEAWEED; FORESTRY; WATERING
- A01G33/00—Cultivation of seaweed or algae
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K61/00—Culture of aquatic animals
- A01K61/10—Culture of aquatic animals of fish
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K61/00—Culture of aquatic animals
- A01K61/10—Culture of aquatic animals of fish
- A01K61/13—Prevention or treatment of fish diseases
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K61/00—Culture of aquatic animals
- A01K61/50—Culture of aquatic animals of shellfish
- A01K61/59—Culture of aquatic animals of shellfish of crustaceans, e.g. lobsters or shrimps
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/20—Animal feeding-stuffs from material of animal origin
- A23K10/22—Animal feeding-stuffs from material of animal origin from fish
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/80—Feeding-stuffs specially adapted for particular animals for aquatic animals, e.g. fish, crustaceans or molluscs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/10—Carbonates; Bicarbonates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/42—Phosphorus; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Environmental Sciences (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Polymers & Plastics (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Biodiversity & Conservation Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Physiology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- Birds (AREA)
- Insects & Arthropods (AREA)
- Biomedical Technology (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
Abstract
本发明公开了一种复合药物组合物及其制备方法和应用。按照重量份数计，复合药物组合物包括：5～10份沙棘黄酮、5～10份小檗碱和6～12份水杨酸。所述复合药物组合物对于东风螺的存活率以及东风螺规格具有显著的提升。此外，本发明还公开了一种在养殖池中控制剑水蚤爆发的方法，栽种长茎葡萄蕨藻以及混养海马，并在养殖水体中添加复合药物组合物。所述方法极大地降低了东风螺养殖过程中剑水蚤的数量，抑制了剑水蚤爆发，并基于此进一步提高了东风螺的存活率以及其规格。
The present invention discloses a composite pharmaceutical composition, a preparation method and an application thereof. In terms of weight, the composite pharmaceutical composition includes: 5 to 10 parts of seabuckthorn flavonoids, 5 to 10 parts of berberine and 6 to 12 parts of salicylic acid. The composite pharmaceutical composition significantly improves the survival rate and specifications of baby snails. In addition, the present invention also discloses a method for controlling the outbreak of sword water fleas in a breeding pond, planting long-stem grape fern algae and mixed breeding of seahorses, and adding the composite pharmaceutical composition to the breeding water. The method greatly reduces the number of sword water fleas in the breeding process of baby snails, inhibits the outbreak of sword water fleas, and further improves the survival rate and specifications of baby snails based on this.
Description
Technical Field
The invention belongs to the technical field of aquatic animal culture, and in particular relates to a compound pharmaceutical composition, application thereof and a method for controlling the outbreak of daphnia.
Background
Babylonia, also called conch, sweet conch, southern conch, etc., belongs to Mollusca phylum (molusca), gastropoda (Gastropoda), front gill subclass (Prosobranchia), new gastropoda (Neogastropoda), moth spiroidae (Buccinidae), babylonia (Babylonia), and is the main cultured shellfish species in our country. Babylonia is a mollusk with male and female variants, the shell of the Babylonia is long and oval, the shell is hard, the surface is smooth, the growth lines are fine, and the shell surface is provided with light brown or yellow brown shell.
In recent years, as the cultivation area is continuously amplified, the eutrophication condition of the seawater body is increasingly aggravated by tail water discharged by cultivation, so that a large number of zooplankton are initiated to reproduce, and the zooplankton such as daphnia on the upper layer of the seawater is remarkably increased. Meanwhile, the culture area of the Babylonia is gradually enlarged, the area of the coast where the bottom water can be pumped is continuously reduced, the situation of water tends to be tense, surface water (surface water) is inevitably adopted, however, even if the surface water is filtered, a plurality of zooplankton, especially the daphnia, can be carried, and the damage to the Babylonia is extremely large.
The daphnia belongs to crustacea of Arthropoda, can gather in a snail pond, and by means of the copepod scratch, the eastern snail is even ingested, the wound can increase the risk of the eastern snail infecting bacteria, and greatly influence the breeding characters such as the growth, the survival rate and the like of the eastern snail. In addition, the inside and outside surfaces of the zooplankton of the daphnia species carry a large number of microorganisms, wherein pathogenic bacteria are not used, and the survival rate, specification and breeding success rate of the Babylonia species are greatly influenced. Therefore, the daphnia disease has become one of the important diseases of the Babylonia breeding industry.
When the common medicine for killing the daphnia is trichlorfon, the common medicine has potential safety risks for the Babylonia and human beings, and once the dosage is slightly deviated, the cultured Babylonia can die, so that the use of the trichlorfon for killing the daphnia has a certain danger.
The patent publication No. CN105660721A discloses a Chinese medicinal composition for preventing and treating daphnia, which comprises, by weight, chinese medicinal materials including 10-15 parts of a small arrow, 5-8 parts of myxoma, 5-8 parts of citrus reticulata leaves, 10-15 parts of sapium sebiferum, and 20-30 parts of swallowtail. Pulverizing the above Chinese medicinal materials, mixing to obtain Chinese medicinal powder, placing into a plurality of bags made of three-layer silk stockings, fastening the bags, placing into fry jar, and continuously soaking for 2-3 days. The method can kill the daphnia in the water body of the weever fries and improve the survival rate of the weever fries. However, the traditional Chinese medicine composition is suitable for fishes instead of Babylonia, continuous soaking is needed for a plurality of days when the traditional Chinese medicine composition is used, continuous running water culture is needed for the Babylonia, and ecological habits are different.
Therefore, there is an urgent need to search for a method of improving survival rate, specification and breeding success rate of Babylonia, and further, for safe and effective control of daphnia.
Disclosure of Invention
In view of the above-mentioned prior art problems, a primary object of the present invention is to provide a composite pharmaceutical composition, which has a significant improvement in survival rate and specification of Babylonia.
The second object of the present invention is to provide a method for preparing a composite pharmaceutical composition.
The third object of the invention is to provide an application of the compound pharmaceutical composition in preparing medicines for improving the survival rate and/or the specification of the Babylonia.
A fourth object of the present invention is to provide the use of a combination pharmaceutical composition for reducing the number of daphnia.
A fifth object of the present invention is to provide a method of controlling the outbreak of daphnia in a lagoon.
A sixth object of the present invention is to provide the use of a method of controlling the outbreak of daphnia in a lagoon for improving the survival rate and/or improving the specification of the Babylonia.
In order to achieve the above object, the present invention is realized by the following technical scheme:
The composite medicine composition comprises, by weight, 5-10 parts of seabuckthorn flavone, 5-10 parts of berberine and 6-12 parts of salicylic acid.
In the invention, the seabuckthorn flavone is rich in active ingredients such as quercetin, isorhamnetin, kaempferol and the like, not only has the functions of enhancing the immunity of the body of the Babylonia, improving the disease resistance of the Babylonia, promoting the growth of the Babylonia, improving the oxidation resistance and the like, but also has the remarkable characteristics of no drug resistance, no drug residue and the like. Furthermore, the berberine has various functions on Babylonia, and can promote the repair of intestinal structural injury, improve the integrity of intestinal mucosa barrier, regulate intestinal flora structure, and also has biological functions of enhancing organism immunity, resisting oxidation and the like. Further, the salicylic acid has the effects of relieving pain, diminishing inflammation, resisting bacteria and inhibiting bacteria, and can prevent and reduce the occurrence of aquaculture water or Babylonia aquaculture diseases.
The inventor finds that the combined application of the seabuckthorn flavone, the berberine and the salicylic acid has the effects of synergistically promoting the growth and development of the Babylonia, reducing the feed coefficient, improving the utilization rate of nutrient substances, improving the flora composition of intestinal tracts, enhancing the immunity and the disease resistance of organisms and the like. Can be used for a long time in the whole Babylonia cultivation period, can prevent and reduce the occurrence of diseases, and avoids the occurrence of large-scale explosive diseases. Can effectively improve the survival rate and the specification of the Babylonia.
Specifically, in the invention, the chemical name of berberine is 5, 6-dihydro-9, 10-dimethoxybenzo [ g ] -1, 3-benzodioxol [5, 6-alpha ] quinolizine hydrochloride dihydrate, and substances with the chemical names are all within the protection scope of the invention and can be reasonably selected by a person skilled in the art.
Preferably, the compound pharmaceutical composition comprises 8-10 parts by weight of seabuckthorn flavone, 7-10 parts by weight of berberine, 8-10 parts by weight of salicylic acid, 1-2 parts by weight of calcium hydrophosphate and 1-2 parts by weight of potassium bicarbonate.
Preferably, the composite pharmaceutical composition further comprises 1-2 parts of a calcium additive and/or 1-2 parts of a potassium additive.
Preferably, the calcium additive is selected from one or more of calcium carbonate, calcium phosphate, calcium gluconate, and calcium chloride.
Preferably, the potassium additive is selected from one or more of potassium chloride, potassium carbonate, potassium dihydrogen phosphate, dipotassium hydrogen phosphate.
Furthermore, the invention discloses a preparation method of the compound pharmaceutical composition, which is to uniformly mix seabuckthorn flavone, berberine and salicylic acid to obtain the compound pharmaceutical composition.
Further, the invention claims the application of the compound pharmaceutical composition in preparing the compound pharmaceutical composition for improving the survival rate and/or the specification of the Babylonia.
Further, the invention claims the use of the above-described combination pharmaceutical composition for reducing the number of daphnia.
Further, the invention claims a method of controlling the outbreak of daphnia in a culture pond, cultivating fern algae and polyculturing hippocampus, and adding the composite pharmaceutical composition to a body of culture water.
Preferably, the planting density of the pteridophyta longifolia is 0.1-0.3 kg/m 2.
Preferably, the cultivation density of the sea horse is 5-10 tails/m 2.
Preferably, the Babylonia is also cultivated in the cultivation pond.
Preferably, the pteridophyte is planted in the culture sand body, and the sea horse is mixedly cultured in the culture water body.
According to the invention, the pteris longifolia and the Hippocampus polyculture are planted in the process of cultivating the Babylonia, and the composite pharmaceutical composition is matched, so that the number of the daphnia is greatly reduced in the process of cultivating the Babylonia, the explosion of the daphnia is inhibited, and the survival rate of the Babylonia and the specification thereof are further improved based on the method. Specifically:
In the process of culturing Babylonia, the sea horse is mixedly cultured in the culture water body, and the sea horse can absorb body type micro plankton such as daphnia, and the like by adopting the straw-shaped kistrodon. The sea horse is utilized for biological control, so that the number of the daphnia magna can be accurately and effectively restrained, the harm of the daphnia magna to the cultivation of the paradise is reduced, and the healthy growth, the survival rate and the high specification of the paradise are ensured. The Babylonia is planted in the Babylonia culture sand layer to provide natural hidden places for the sea horse, and meanwhile, the Babylonia can absorb elements such as N, P remained in the water body, so that the effect of purifying water quality is achieved.
In addition, the inventor also discovers that the ecological system for culturing the Babylonia, the Hippocampus and the Botrytis cinerea also has certain balance and stability, and the mixed culture of the Hippocampus and the planting of the Botrytis cinerea do not harm the ecological system for culturing the Babylonia.
Further, the inventors found through researches that the composite pharmaceutical composition adopted by the invention also has excellent promoting effect on the system of Botrytis cinerea and the polyculture of sea horses. On one hand, the compound pharmaceutical composition can also provide sufficient and needed key nutrients for the Botrytis cinerea and promote the division and growth of cells of Botrytis cinerea, so that the algae are more luxuriant, and the rapid growth and propagation of the Botrytis cinerea are realized.
On the other hand, the compound pharmaceutical composition has the following effects of (1) improving the survival rate, and reducing the risks of illness and death by enhancing the immunity and disease resistance of the hippocampus, thereby improving the survival rate. (2) Promoting growth and development, and optimizing nutrition absorption and metabolism of Hippocampus, and improving growth speed and yield. (3) The adaptability to the environment is enhanced, so that the sea horse can better adapt to the change of the culture environment, such as the fluctuation of water quality, temperature and the like.
The invention provides an ecological friendly and sustainable way to cope with the outbreak of the daphnia, and reduces the potential pollution to the breeding environment and the adverse effect on the Babylonia. The strategy based on biological control is beneficial to improving the economic benefit and the sustainability of the large-scale production of the Babylonia, and provides powerful support and guarantee for the green development of the breeding industry.
Preferably, in the process of cultivating Babylonia, the water temperature of the cultivation water body is kept at 24-28 ℃, the dissolved oxygen is 5-6 mg/L, and the salinity is 26-30.
Preferably, the adding mode of the composite medicine composition is at least one of the following (a) - (d):
(a) The dosage of the composite medicine composition is 3-10 g/m 3;
(b) The compound pharmaceutical composition is added once every 10-15 days in a whole pool;
(c) Stopping water injection before adding the pharmaceutical composition, stopping oxygen supply after splashing for 5-10 minutes, continuously changing water for 1-2 hours;
(d) The combination pharmaceutical composition is used at night.
Preferably, when the composite pharmaceutical composition is used at night, the white light is turned on to irradiate the culture water body so as to induce the daphnia in the culture water body to concentrate at one place. More specifically, the area irradiated by the white lamp can occupy 1/6-1/8 of the area of the culture pond.
In particular, in the present invention, a sea horse which is clean in body surface, free of parasites and has a good state of vitality can be selected. More specifically, the kind of Hippocampus may be Hippocampus kelvin (Hippocampus erectus) and/or Hippocampus abdominus (Hippocampus abdominalis).
Specifically, the Babylonia is Babylonia genus (Babylonia) including, but not limited to, babylonia (Babylonia areolata), babylonia (lutosa), babylonia (Babylonia formosae), and the like.
Compared with the prior art, the invention has the following beneficial effects:
The invention provides a compound pharmaceutical composition which has obvious improvement on the survival rate of Babylonia and the specification of Babylonia. On the basis, the invention plants the pteris longifolia and the Hippocampus polyculture in the process of cultivating the Babylonia, and adds the composite pharmaceutical composition in the cultivation water body, thereby greatly reducing the number of the daphnia in the process of cultivating the Babylonia, inhibiting the burst of the daphnia and further improving the survival rate and the specification of the Babylonia based on the method.
Drawings
FIG. 1 is a schematic representation of a cleaned, ready-to-deliver Botrytis cinerea.
Fig. 2 and 3 are schematic views of the weight of Botrytis cinerea weighed in advance according to the planting density and placed in a culture pond.
FIG. 4 is a schematic diagram of a pool for polyculturing Hippocampus, botrytis cinerea and Babylonia.
Detailed Description
The invention is further illustrated in the following drawings and specific examples, which are not intended to limit the invention in any way. Unless specifically stated otherwise, the reagents, methods and apparatus employed in the present invention are those conventional in the art.
The seabuckthorn flavone, the berberine and the salicylic acid used in the invention are purchased from Shanghai Yuan Ye biological technology Co.
Example 1 preparation of a Complex pharmaceutical composition
According to the weight portions, 10 portions of seabuckthorn flavone, 10 portions of berberine, 8 portions of salicylic acid, 2 portions of calcium hydrophosphate and 2 portions of potassium bicarbonate are respectively selected and evenly mixed to prepare the composite pharmaceutical composition.
Example 2 preparation of a Complex pharmaceutical composition
According to the weight portions, 10 portions of seabuckthorn flavone, 10 portions of berberine, 10 portions of salicylic acid, 1 portion of calcium hydrophosphate and 2 portions of potassium bicarbonate are respectively selected and evenly mixed to prepare the composite pharmaceutical composition.
Example 3 preparation of a Complex pharmaceutical composition
According to the weight portions, 9 portions of seabuckthorn flavone, 5 portions of berberine, 8 portions of salicylic acid, 2 portions of calcium hydrophosphate and 1 portion of potassium bicarbonate are respectively selected and evenly mixed to prepare the composite pharmaceutical composition.
Example 4 preparation of a Complex pharmaceutical composition
According to the weight portions, 8 portions of seabuckthorn flavone, 7 portions of berberine, 6 portions of salicylic acid, 2 portions of calcium hydrophosphate and 2 portions of potassium bicarbonate are respectively selected and evenly mixed to prepare the composite pharmaceutical composition.
EXAMPLE 5 cultivation of Babylonia
The test adopts a 3m multiplied by 5m multiplied by 0.5m indoor cement pond as the Babylonia culture pond. The outside sea water is extracted to a filter tank through a sand filter well, and enters a culture tank after ultraviolet disinfection. The young Babylonia areolata with the shell length of 10-15 mm is put in, and the culture density of each pond is 800 grains/m 2. During cultivation, the water in the cultivation pond is controlled at 24-28 ℃ in water temperature, dissolved oxygen is 5-6 mg/L, and salinity is 26-30. The composite pharmaceutical composition prepared in example 1 is adopted to spray the bait balwave fish once every 12 days in the whole pond after the bait balwave fish is fed in the afternoon of the culture pond, and the dosage of the composite pharmaceutical composition is 8g/m 3 (based on the volume of the culture water body). The water injection was stopped before the sprinkling, and after 5 minutes the oxygen supply was stopped, the state was continued for 1 hour, and then the water valve was opened to change the water. The composite medicine composition is used for night. The growth situation of the eastern conch in the culture pond needs to be observed every day, and if dead individuals or clusters are found, the dead individuals or clusters should be cleaned out in time.
EXAMPLE 6 cultivation of Babylonia
This example differs from example 5 in that the composite pharmaceutical composition was prepared using example 2.
EXAMPLE 7 cultivation of Babylonia
This example differs from example 5 in that the compound pharmaceutical composition was prepared using example 3.
Example 8A method of controlling the outbreak of Isaria in the Large Scale production of Babylonia
The test adopts a 3m multiplied by 5m multiplied by 0.5m indoor cement pond as the Babylonia culture pond. The outside sea water is extracted to a filter tank through a sand filter well, and enters a culture tank after ultraviolet disinfection. The young Babylonia areolata with the shell length of 10-15 mm is put in, and the culture density of each pond is 800 grains/m 2. Planting Botrytis cinerea on the culture sand, wherein the density is 0.2kg/m 2, the mixed culture body in the culture pond is 1cm of Hippocampus kelvin, and the density is 6 tails/m 2. During cultivation, the water in the cultivation pond is controlled at 24-28 ℃ in water temperature, dissolved oxygen is 5-6 mg/L, and salinity is 26-30. The composite pharmaceutical composition prepared in example 1 is adopted to spray the bait balwave fish once every 12 days in the whole pond after the bait balwave fish is fed in the afternoon of the culture pond, and the dosage of the composite pharmaceutical composition is 8g/m 3 (based on the volume of the culture water body). The water injection was stopped before the sprinkling, and after 5 minutes the oxygen supply was stopped, the state was continued for 1 hour, and then the water valve was opened to change the water. The compound medicine composition is used for night, and a white lamp above the culture pond is turned on at the moment to induce the daphnia on the water surface of the culture pond to concentrate at one place, and the irradiation area of the daphnia accounts for about 1/8 of the area of the culture pond. The growth situation of the Babylonia, the Hippocampus and the Botrytis cinerea in the culture pond is observed every day, and if dead individuals or clusters are found, the Babylonia, the Hippocampus and the Botrytis cinerea should be cleaned out in time.
Example 9A method for controlling the outbreak of Isaria in the Large Scale production of Babylonia
This example differs from example 8 in that the composite pharmaceutical composition was prepared using example 2.
Example 10 method of controlling an outbreak of a Metridia in the Large Scale production of Babylonia
This example differs from example 8 in that the compound pharmaceutical composition was prepared using example 3.
Comparative example 1
The difference between this comparative example and example 5 is that the composite pharmaceutical composition was not prepared using example 1.
Comparative example 2
The difference between this comparative example and example 5 is that the combination pharmaceutical composition of example 1 contains only Hippophae flavone and berberine.
Comparative example 3
The difference between this comparative example and example 5 is that the combination pharmaceutical composition of example 1 contains only Hippophae flavone and salicylic acid.
Comparative example 4
The difference between this comparative example and example 5 is that the combination pharmaceutical composition of example 1 contains only berberine and salicylic acid.
Comparative example 5
The difference between this comparative example and example 5 is that the combination pharmaceutical composition of example 1 contains only berberine.
Comparative example 6
The difference between this comparative example and example 5 is that the combination pharmaceutical composition of example 1 contains only salicylic acid.
Comparative example 7
The difference between this comparative example and example 8 is that the composite pharmaceutical composition was not prepared using example 1.
Comparative example 8
The difference between this comparative example and example 8 is that the composite pharmaceutical composition was not prepared using example 1, and that the hippocampus was not mixotrophic.
Comparative example 9
The difference between this comparative example and example 8 is that the composite pharmaceutical composition was not prepared using example 1, and that no Botrytis cinerea was grown.
Test case
The cultivation period is 2 months. The density of the daphnia in the pond was measured at each of the initial stage of cultivation and 2 months. Extracting randomly for 3 times, culturing Chi Shuiyang at 1L each time, filtering with a zooplankton filter screen of 30 μm, spreading out the sampling work of zooplankton in water, and detecting. The filter screen is inverted, distilled water is used for washing, a water sample containing zooplankton is obtained, the water sample is brought into a laboratory, a proper amount of formaldehyde (the formaldehyde content reaches 4%) is added to fix the zooplankton after the water sample is concentrated to 50mL, meanwhile, the water sample is uniformly stirred by means of a glass rod, the water sample is kept stand for 1 minute, the superfluous water on the upper layer is poured out, the residual water sample is transferred into a culture dish, the number of the daphnia magna adults and larvae is observed and counted through a microscope, and corresponding records are made. The observation count was continuously performed 3 times, and the average value was regarded as the final measurement value. The dead snails were picked up daily and recorded as the number of deaths of the Babylonia.
Screw survival= (total number of seedlings-number of dead eastern conch)/total number of seedlings x 100%.
1 Kg of Babylonia quadricarina is taken from the culture pond for 3 times randomly, and the average value is the Babylonia quadricarina specification (only per kg).
Hippocampal yield dead hippocampus was picked up daily and recorded.
And (3) yield of the Botrytis cinerea, namely, collecting the Botrytis cinerea after 2 months of cultivation, and draining off the weight (kg).
The above statistical results are shown in table 1 below.
TABLE 1
From the above examples 5 to 7, it is known that the survival rate and specification of Babylonia can be significantly improved by adopting the composite pharmaceutical composition provided by the invention. The survival rate of the Babylonia is more than or equal to 84.4 percent, and the specification of the Babylonia is within 441/kg. Further, as can be seen from the above examples 8 to 10, the composite pharmaceutical composition provided by the invention can be used for remarkably improving the survival rate and specification of Babylonia and reducing the density of daphnia in the culture water body by combining planting of Babylonia longifolia and mixed culture of Hippocampus in the Babylonia culture process. The survival rate of the Babylonia is more than or equal to 95.5 percent, the specification of the Babylonia is within 438/kg, and the density of the daphnia is less than or equal to 13/L.
From examples 5, comparative example 1 and comparative examples 2 to 6, the combined use of seabuckthorn flavone, berberine and salicylic acid has the effects of synergistically promoting the growth and development of the Babylonia and improving the survival rate of the Babylonia. And it is difficult to achieve the technical effects of the present invention by using one or both of the components alone.
As is clear from examples 8, comparative examples 1 and 7, it is difficult to achieve the technical effects of the present invention by merely cultivating the pteridophyte and mixedly cultivating the sea horse during cultivation, the survival rate and the specification of the Babylonia in comparative examples 1 and 7 are significantly lower than those in example 8, and the sea horse yield and the algae yield are significantly lower than those in example.
The foregoing examples are illustrative only and serve to explain some features of the method of the invention. The claims that follow are intended to claim the broadest possible scope as conceivable and the embodiments presented herein are demonstrated for the applicant's true test results. It is, therefore, not the intention of the applicant that the appended claims be limited by the choice of examples illustrating the features of the invention. Some numerical ranges used in the claims also include sub-ranges within which variations in these ranges should also be construed as being covered by the appended claims where possible.
Claims (5)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202510106051.0A CN119924340A (en) | 2024-07-05 | 2024-07-05 | Method for controlling flea outbreak |
| CN202410897859.0A CN118873569B (en) | 2024-07-05 | 2024-07-05 | Composite pharmaceutical composition and its application and method for controlling sword flea outbreak |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410897859.0A CN118873569B (en) | 2024-07-05 | 2024-07-05 | Composite pharmaceutical composition and its application and method for controlling sword flea outbreak |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202510106051.0A Division CN119924340A (en) | 2024-07-05 | 2024-07-05 | Method for controlling flea outbreak |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN118873569A CN118873569A (en) | 2024-11-01 |
| CN118873569B true CN118873569B (en) | 2025-02-25 |
Family
ID=93234055
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202510106051.0A Pending CN119924340A (en) | 2024-07-05 | 2024-07-05 | Method for controlling flea outbreak |
| CN202410897859.0A Active CN118873569B (en) | 2024-07-05 | 2024-07-05 | Composite pharmaceutical composition and its application and method for controlling sword flea outbreak |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202510106051.0A Pending CN119924340A (en) | 2024-07-05 | 2024-07-05 | Method for controlling flea outbreak |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN119924340A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105724284A (en) * | 2016-02-16 | 2016-07-06 | 福建港德水产有限公司 | Ecological cultivating method for mixed cultivation of sea horses and caulerpa lentillifera |
| CN116602246A (en) * | 2023-06-07 | 2023-08-18 | 广东海洋大学 | A kind of polyculture method of Dongfeng snail, fish and sargassum |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017027971A1 (en) * | 2015-08-17 | 2017-02-23 | Delivra Inc. | Transdermal formulations for delivery of berberine compounds, and their use in the treatment of berberine-responsive diseases and conditions |
| IL302224A (en) * | 2020-10-22 | 2023-06-01 | Paxmedica Inc | Administration of anti-purinergic preparations for the treatment of disorders of the nervous system |
| CN117618450B (en) * | 2023-12-21 | 2024-04-19 | 广东海洋大学 | A drug additive and its preparation method and application in preventing and treating Babylonia snail syndrome |
| CN117752776B (en) * | 2024-02-22 | 2024-05-03 | 广东海洋大学 | A pharmaceutical preparation and its application in preparing a medicine for treating stress injury of babylonia after transportation |
| CN117959339B (en) * | 2024-03-28 | 2024-06-21 | 广东海洋大学 | Pharmaceutical composition and its application in preparing product for restoring the fecundity of baby snails |
-
2024
- 2024-07-05 CN CN202510106051.0A patent/CN119924340A/en active Pending
- 2024-07-05 CN CN202410897859.0A patent/CN118873569B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105724284A (en) * | 2016-02-16 | 2016-07-06 | 福建港德水产有限公司 | Ecological cultivating method for mixed cultivation of sea horses and caulerpa lentillifera |
| CN116602246A (en) * | 2023-06-07 | 2023-08-18 | 广东海洋大学 | A kind of polyculture method of Dongfeng snail, fish and sargassum |
Also Published As
| Publication number | Publication date |
|---|---|
| CN118873569A (en) | 2024-11-01 |
| CN119924340A (en) | 2025-05-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105165665A (en) | Aquaculture method and aquaculture system | |
| CN102177868B (en) | Method for pond three-dimensional (3D) culture of Chinese prawns | |
| CN102715105A (en) | Industrialization cultivation method for shrimp seed of macrobrachium rosenbergii | |
| CN106259097A (en) | A kind of ecological cultivation method of Cyprinus carpio | |
| CN103563803B (en) | A kind of cultural method reducing stichopus japonicus damage by disease and insect and occur | |
| CN105309360B (en) | A kind of pearl dragon wholesale grouper and the method for Marsupenaeus japonicus mixed breeding control white spot syndrome | |
| CN103478033B (en) | Nuisanceless eel farming method | |
| CN106259096A (en) | A kind of cultural method of Ctenopharyngodon idellus | |
| CN106688970A (en) | Method for artificially breeding fingerlings of siganus vulpinus in indoor environments | |
| CN102178296B (en) | Purple sweet potato drink and preparation process thereof | |
| CN104642089B (en) | A kind of polyculture method of fragrant plant mentioned in ancient texts and grouper | |
| KR100953994B1 (en) | Method of producing tegillarca granosa seedling | |
| CN103563806B (en) | Cultivation method capable of reducing stichopus japonicus disease and pest injuries with corrosion inhibition nanometer materials | |
| CN105409848A (en) | Method for controlling bacterial diseases by co-culturing Siganus ConcatenaluJ and Penaeus japonicus | |
| CN118873569B (en) | Composite pharmaceutical composition and its application and method for controlling sword flea outbreak | |
| CN107616120A (en) | A kind of cultural method of selenium-rich fish | |
| CN106259060A (en) | A kind of Cobitidae fish fry breeding method | |
| CN103430871A (en) | Scientific and precise artificial cultivation method for four-gill weever | |
| CN111066705A (en) | Improved river crab ecological breeding method | |
| CN100512843C (en) | Chinese herbal composite prescription for controlling sea fish paralembus digitiformis | |
| CN106745779B (en) | Water body treatment construction maintenance method and artificial lake | |
| CN110521669B (en) | Green giant spiny frog breeding method | |
| CN103891636A (en) | Method for preventing and treating fish diseases | |
| CN103193323B (en) | Method for ecologically remedying water by utilizing aizoon stonecrop | |
| CN112772483A (en) | Water treatment scheme for zero-emission soil pond culture of penaeus vannamei boone |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |